Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.

MLA

Kanabar, Dipti, et al. “Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.” Journal of Medicinal Chemistry, vol. 65, no. 13, July 2022, pp. 8975–97. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.2c00190.

APA

Kanabar, D., Goyal, M., Kane, E. I., Chavan, T., Kabir, A., Wang, X., Shukla, S., Almasri, J., Goswami, S., Osman, G., Kokolis, M., Spratt, D. E., Gupta, V., & Muth, A. (2022). Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer. Journal of Medicinal Chemistry, 65(13), 8975–8997. https://doi.org/10.1021/acs.jmedchem.2c00190

Chicago

Kanabar, Dipti, Mimansa Goyal, Emma I Kane, Tejashri Chavan, Abbas Kabir, Xuechun Wang, Snehal Shukla, et al. 2022. “Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.” Journal of Medicinal Chemistry 65 (13): 8975–97. doi:10.1021/acs.jmedchem.2c00190.